AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Voyageur Pharmaceuticals Ltd.
Video analysis: VYYRF
All videosNo video analysis for this stock yet. Request one from our team.
News: VYYRF
Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment
CALGARY, Alberta – TheNewswire - September 9, 2026 – Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) (“ Voyageur ” or the “ Company ”), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has achieved the first milestone under its non-dilutive Collaboration and Funding Agreement with Bayer AG (“ Bayer ”) dated February 10, 2026 (the “ Agreement ”) by submitting a complete feasibility work plan and timetable which has been approved by Bayer. (Collaboration funding news https://finance.yahoo.com/news/voyageur-pharmaceuticals-announces-collaboration-bayer-144926270.html )
Voyageur Pharmaceuticals Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing
CALGARY, Alberta – August 10, 2026 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) (“Voyageur” or the “Company”), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to provide an update on the advancement of its proprietary patent-pending Mueller iodine extraction process. The Mueller process is being developed to recover high-purity iodine from iodine-rich oilfield brine, supporting Voyageur's strategy to establish a domestic iodine supply for the North American radiology contrast media market, while offering oil and gas producers and midstream water operators a new pathway to generate value from produced brine. Recent laboratory work has successfully produced iodine at 99.8% purity, with overall process recovery exceeding 90%.
Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker
Calgary, Alberta--(Newsfile Corp. - July 17, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has engaged Red Cloud Securities Inc. ("Red Cloud"), subject to all required regulatory approvals, including the approval of the TSX Venture Exchange (the "TSXV") to provide market stabilization and liquidity services to the Company in compliance with the policies and guidelines of the TSXV and other applicable legislation, pursuant to letter of engagement entered into between the Company and Red Cloud effective July 14, 2026 (the "Agreement").
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
CALGARY, Alberta – TheNewswire - June 23, 2026 – Voyageur Pharmaceuticals Ltd . ( TSX.V: VM ) (OTC Pink: VYYRF) (“ Voyageur ” or the “ Company ”), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has engaged Fluor Corporation (“ Fluor ”), a leading global engineering, procurement, construction and maintenance firm, to complete comprehensive feasibility studies for two strategic projects that will advance the Company's vertically integrated North American supply chain for radiology contrast drugs. The engagement covers:
Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway
CALGARY, Alberta – June 18, 2026 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) (“Voyageur” or the “Company”), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce it is evaluating three potential locations in the United States for its planned integrated iodine and barium contrast drug manufacturing facility. The Company is completing a comprehensive technical, regulatory, economic, and logistical analysis of candidate sites. Key evaluation criteria include proximity to iodine brine sources (expected to support an estimated +70% of future revenue), logistics, infrastructure, access to skilled labour, and the strength of government incentive packages. Voyageur is actively engaging with economic development authorities across multiple U.S. jurisdictions. The final site will be selected based on the most attractive overall combination of factors, with a strong emphasis on the incentive and support packages offered. This competitive process is designed to optimize project economics and accelerate development timelines.
